SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)

Keating et al., NCT04478019, SHIELD, NCT04478019, Jun 2022

PVP-I for COVID-19

13th treatment shown to reduce risk in February 2021, now with p = 0.0000000037 from 21 studies.

No treatment is 100% effective.
Protocols combine treatments.

245 participant povidone-iodine + chlorhexidine prophylaxis RCT with results not reported over 4 years after completion.
2 povidone-iodine RCTs have results missing long after expected1,2
The trials report a total of 295 patients, with 1 trial having actual enrollment of 245, and the other estimated.
Study covers chlorhexidine and povidone-iodine.
Keating et al., 30 Jun 2022, Randomized Controlled Trial, USA, this trial uses multiple treatments in the treatment arm (combined with chlorhexidine) - results of individual treatments may vary, trial NCT04478019 (history) (SHIELD). Contact: ns2@medicine.wisc.edu, dshirley@medicine.wisc.edu, jakeating@medicine.wisc.edu, SHIELD@medicine.wisc.edu, klhaight@medicine.wisc.edu, jperzynski@medicine.wisc.edu, mzimbric@medicine.wisc.edu.